[Experience with fluspirilene in gerontopsychiatry (author's transl)].
The paper reports on an open study of flupirilene administration in ten previously untreated female outpatients with paranoid symptomatology who were of advanced age. In eight of the ten patients who had been included in the 12-week study the authors observed a remission particularly of delusion dynamics, delusional intuitions, delusional perceptions, and restlessness as well as excitment. The therapy failed in two patients. Preexisting cerebro-organic impairments deteriorated partly, whereas vegetative and extrapyramidal side effects were of only moderate intensity. Hence, fluspirilene proved to be a depot neuroleptic with good antipsychotic effect in outpatient treatment of paranoid psychoses of patients of advanced age. However, especially in patients of advanced age. However, especially patients with preorganic brain syndrome, the obviously sedating and retarding effects of this drug must be taken into account, since they may contribute to further disturbance of the impaired cerebral function.
D000328:Adult; D000368:Aged; D003702:Delusions / Q000188:drug therapy; D003704:Dementia / Q000188:drug therapy*; D005484:Fluspirilene / Q000627:therapeutic use*; D006801:Humans; D010259:Paranoid Disorders / Q000188:drug therapy; D013141:Spiro Compounds / Q000627:therapeutic use*
D013141:Spiro Compounds; D005484:Fluspirilene
Erfahrungen mit Fluspirilene in der Gerontopsychiatrie.